Criteria for a Clinically Informative Serum Biomarker in Acute Ischaemic Stroke: A Review of S100B

Pooja Dassan a Geoffrey Keir b Martin M. Brown a

a Stroke Research Group and b Department of Neuroimmunology, UCL Institute of Neurology, National Hospital of Neurology and Neurosurgery, London, UK

Key Words
S100B protein • Biomarker • Acute ischaemic stroke

Abstract
Background and Purpose: Serum S100B has been widely studied as a biomarker in acute ischaemic stroke. The main objective of this review was to appraise the published literature on S100B and determine its clinical applicability. Methods: Medline was searched to identify studies on S100B (or S-100B) in acute ischaemic stroke. The authors have proposed the criteria for a clinically informative serum biomarker for acute ischaemic stroke, and relevant articles relating to these criteria were then selected. Results: Studies have shown that S100B has a low specificity for acute ischaemic stroke because of its tendency to be raised from extracranial sources. Data regarding S100B kinetics compiled from 6 longitudinal studies show that serum levels are not raised immediately following acute ischaemic stroke and peak 3 days after symptom onset. However, serum S100B levels correlate well with infarct volume and are higher in stroke patients at risk of malignant infarction or haemorrhagic transformation after thrombolysis. In addition, serum S100B levels correlate well with functional outcome. Conclusion: The evidence suggests that S100B is not a valuable biomarker for diagnosing acute ischaemic stroke. Instead, it may have a more promising role in non-specialist hospitals, as an additional tool for identifying patients at increased risk of specific early neurological complications after stroke and as a surrogate marker of cerebral damage and functional outcome, particularly in a research setting.

Copyright © 2009 S. Karger AG, Basel
Accessible online at: www.karger.com/ced
neurological complications (e.g. malignant cerebral infarction), and (3) evaluating the severity of brain damage to predict final outcome.

Serum S100B has received most attention in the literature over the last decade and continues to be widely investigated as a biomarker in several different aspects of acute stroke care. However, its utility to clinicians remains uncertain. We reviewed and appraised the published literature on S100B to determine its clinical applicability in acute ischaemic stroke.

**Potential Use for Biomarkers**

**Acute Stroke Diagnosis**

In order to maximise treatment benefits with recombinant tissue plasminogen activator within the therapeutic window, it is important to make an accurate and early diagnosis of acute ischaemic stroke. In most hospitals, the diagnosis of an acute ischaemic stroke is made solely on clinical grounds after excluding cerebral haemorrhage by brain CT [2]. CT is the most reliable method for demonstrating haemorrhage within the first week after onset [3]. However, the CT scan is normal in about 30% of acute ischaemic strokes, especially within the first few hours after onset [4]. Other CT modalities have also been shown to be very useful in the acute setting and include CT angiography and CT perfusion. The former provides a rapid and reliable method for imaging the intracranial vasculature. Alternatively, CT perfusion allows clinicians to quantify the cerebral blood flow to the potentially ischaemic area of brain tissue acutely in ischaemic stroke patients. Furthermore, with the advent of newer MR sequences, including diffusion-weighted and perfusion-weighted imaging, it is now possible to identify ischaemic tissue at risk of infarction and therefore better selection of potential candidates for thrombolysis therapy, even beyond the therapeutic window [5]. However, despite the emergence of these new imaging modalities, unfortunately they are still not widely available within an emergency setting. Hence, a diagnostic biomarker of acute cerebral infarction, developed as a rapid-response testing kit, would have a valuable role in confirming the diagnosis of acute stroke, particularly in diagnostically challenging cases when the CT findings are normal or equivocal.

Substantial progress has already been made in improving stroke recognition, with the development of simple tools designed to help paramedics recognise acute stroke, e.g. the Face Arm Speech Test [6], the use of which has enabled paramedics to achieve a diagnostic accuracy of between 80 and 95% for acute stroke [7]. Therefore, a valuable diagnostic biomarker for acute stroke would need to achieve a diagnostic sensitivity of >90% to be truly useful in the emergency room.

A number of conditions mimic and confound the diagnosis of acute ischaemic stroke. Between 7 and 25% of patients seen with suspected stroke in the general medical and emergency department settings subsequently turn out to have a non-stroke diagnosis [8, 9]. Examples of common stroke mimics include cerebral tumour, postictal paresis and metabolic disturbances such as hypoglycaemia. Hypoglycaemia and cerebral tumours can be reliably excluded by a bedside blood test and CT imaging, respectively, but other stroke mimics such as postictal paresis cause more diagnostic confusion. As a result, it is often difficult to exclude common stroke mimics, even after clinical evaluation and brain CT.

**Identification of Early Neurological Complications**

Between 25 and 35% of patients who suffer an acute ischaemic stroke experience early neurological complications in the first 48–72 h [10]. This is associated with worse outcome [11]. Biomarkers could have a role in predicting which patients are at high risk of two potential causes of early deterioration, malignant cerebral oedema and symptomatic haemorrhagic transformation.

Severe brain oedema complicating large middle cerebral artery infarcts can be fatal in cases where transtentorial herniation occurs and early decompressive craniotomy is the life-saving treatment of choice [12]. A biomarker able to identify patients at high risk of developing malignant infarction would facilitate early surgical intervention.

Symptomatic haemorrhagic transformation is an important complication of thrombolysis. Recent MRI-based studies suggest that post-stroke blood-brain barrier dysfunction is an important step in the development of cerebral haemorrhage after thrombolysis therapy [13]. Detection of a biomarker sensitive to blood-brain barrier damage might allow clinicians to avoid thrombolysis in patients who are at an increased risk of cerebral haemorrhage.

**Surrogate Marker of Brain Damage and Final Outcome**

It is logical to suppose that the serum level of a biomarker might correlate with the severity of brain damage and could therefore be used as a surrogate marker to monitor the effectiveness of treatment. To validate this
use, the levels of the biomarker should correlate with infarct size and final outcome. A reliable prediction of prognosis early after onset of stroke would also allow better forward planning, facilitate the selection of suitable treatment strategies and enable the clinician to give accurate information to patients and carers. A number of methods of predicting outcome, including measuring infarct volume, have been developed, but none have proven to be sufficiently good indicators to enter routine practice.

Criteria for an Informative Biomarker for Acute Ischaemic Stroke

In order to evaluate the clinical applicability of S100B in acute stroke care, we propose a set of criteria to assess the value of a biomarker in the management of acute ischaemic stroke, based on the above requirements. We propose different criteria for each potential area of use, as follows.

A useful biomarker for acute stroke diagnosis should be:
• sensitive to cerebral infarction, including small-volume infarcts (lacunar infarction) not visible on CT;
• brain specific (ideally specific to cerebral infarction);
• detectable soon after onset of the ictus, ideally within an hour of onset;
• able to distinguish between cerebral infarction and common stroke mimics in the emergency room.

A useful biomarker for the prediction of early neurological complications would either:
• identify patients at high risk of malignant cerebral infarction, or
• identify patients at high risk of haemorrhagic transformation after thrombolysis.

A biomarker useful in estimating the extent of cerebral damage, monitoring treatment response and/or predicting prognosis should have serum levels that:
• correlate with infarct volume;
• correlate with measures of final outcome.

Search Strategy

A literature search was conducted using Medline (January 1950 to April 2008) to identify articles on S100B in acute ischaemic stroke. The search criteria included the terms S100 or S-100, S100B or S-100B, marker or biomarker and one or more of the following terms: stroke, infarction, cerebral ischaemia, cerebral infarction. All patients with primary intracerebral haemorrhage were excluded, and therefore, if studies did not provide separate results for patients with acute ischaemic stroke, they were excluded. We identified 13 relevant studies in accordance with the objectives of the study, and a further 3 additional studies were identified from the bibliographies of the retrieved articles.

Distribution and Action

Protein S100B belongs to a large multigenic family of calcium-modulated proteins (S100 proteins). They get their name from the fact that they are soluble in 100% saturated ammonium sulphate [14]. S100B is found in abundance in the astroglial compartment of the brain, in the Schwann cells of the peripheral nervous system and extraneuronally in melanocytes, adipocytes and chondrocytes [15].

Traditionally, S100B has been considered a reliable marker of astrocytic brain damage. However, a recent study has shown that S100B is localised in many cell types in the human brain including astrocytes, oligodendrocytes, choroid plexus epithelium and neurones [16]. It has also been suggested that S100B may be a marker of blood–brain barrier dysfunction rather than specifically glial damage [17].

S100B and Diagnosis of Cerebral Infarction

Sensitivity to Cerebral Infarction

Several studies have reported that serum S100B levels are significantly raised following cerebral infarction [18–27]. A summary of the main clinical studies published on S100B in acute ischaemic stroke is given in table 1. These studies have shown that serum S100B levels are raised within the first 3 days after acute ischaemic stroke onset. Patients with large-artery, cortical infarcts have higher serum S100B levels compared to patients with lacunar infarcts [19–21, 25]. However, it is plausible that these results may be skewed, as the subjects with cortical infarcts in these studies had larger infarct volumes. This makes it difficult to infer the relative contribution of the location and the volume of infarction.

One study reported that patients with transient ischaemic attack or normal CT brain imaging at onset have significantly lower serum S100B levels, with little variation over time, compared to patients with an appreciable neurological deficit and abnormal brain imaging at onset [23].
Brain Specificity
S100B is not specific to cerebral infarction. Levels are raised in other neuropathologies including traumatic brain injury [31]. In addition, S100B can be released from extracranial malignancies including schwannoma, melanoma and neuroblastoma [15, 32].

Detectability Soon after Onset
Evaluation of the temporal profile of S100B release after acute ischaemic stroke has shown that serum levels are not raised immediately after the ictus [20–25]. We have extracted serum S100B measurements over time from 6 longitudinal studies. Figure 1 shows the mean S100B level at each time point. The compiled data show that there is a gradual increase in levels starting at 8–10 h after symptom onset, followed by a peak at 72 h...
Serum Biomarker in Acute Ischaemic Stroke

and then a subsequent drop in levels at 96 h. One longitudi-

dinal study found that even patients with a large infarct

volume of $≥5 \text{ cm}^3$ on initial CT did not have increased
S100B levels until 10 h after the ictus [20].

Differentiation from Stroke Mimics

We were unable to find any studies which have com-
pared S100B as an independent marker, rather than as
part of a panel, between patients with acute ischaemic
stroke and stroke mimics.

Use of S100B in a Panel

Attempts have been made to improve the diagnostic
utility of S100B levels by including S100B as part of a
panel of markers in order to improve the sensitivity of
diagnosing acute stroke. In one study, the markers in-
cluded in the panel were: S100B; B-type neurotrophic
growth factor; von Willebrand factor; matrix metallo-
proteinase 9, and monocyte chemotactic protein 1 [33].
The authors concluded that the panel of all 5 markers
provided a higher diagnostic sensitivity (91.7%) and
specificity (93%) for diagnosing acute ischaemic stroke
for samples taken within 6 h, as compared to using any
of the markers individually. A second study investigated
a panel of markers made up of: S100B, matrix metallo-
proteinase 9, vascular cell adhesion molecule and von
Willebrand factor [34]. The authors claimed a sensitivity
and specificity of 90% for predicting stroke using this
panel. However, despite quoting fairly high sensitivities
and specificities in both these studies, one major limita-
tion is that the majority of the control population in both
these studies were age-matched subjects without neuro-
logical symptoms. However, Laskowitz et al. [35] studied
a panel of 5 biomarkers, including brain natriuretic pep-
tide, C-reactive protein, D-dimer, matrix metallopro-
teinase 9 and S100B in patients with suspected acute
stroke (including stroke mimics). These authors report-
ed a much lower level of sensitivity (81%) and specificity
(70%) for predicting acute ischaemic stroke than the pre-
vious 2 studies.

S100B and Prediction of Early Neurological
Complications

One study has shown that a single S100B measurement
of $>1.03 \mu\text{g/l}$ taken at 24 h after onset of stroke provided
a fairly high sensitivity (94%) and specificity (83%) for
predicting malignant infarction in patients with proxim-
al middle cerebral artery occlusion [29]. In this study,
16 patients out of a total of 51 developed malignant in-
farction.

Another recent study reported that median prethrom-
bolysis serum S100B levels were higher in patients who
later incurred haemorrhagic transformation (symptom-
atic or asymptomatic) after thrombolysis therapy than
those without haemorrhage (0.14 vs. 0.11 $\mu\text{g/l}; p = 0.017$)[30]. They reported that a pretreatment S100B level of
$>0.23 \mu\text{g/l}$ (the median S100B level in healthy individuals
was 0.06 $\mu\text{g/l}$) had a sensitivity and specificity for pre-
dicting severe parenchymal haemorrhage of 46 and 82%,
respectively.

S100B and Estimating the Extent of Cerebral
Damage, Monitoring Treatment Response and/or
Predicting Outcome

Several studies have shown that serum S100B levels
measured in samples taken more than 24 h after stroke
onset demonstrate a strong correlation with the degree of
neurological deficit and the final infarct volume [19, 20,
22, 25, 26, 29, 30]. However, S100B measurements taken
within 2 h of stroke onset do not correlate with National
Institute of Health Stroke Scale scores at onset, early isch-
aemic changes on CT brain or with the infarct volume
[27].

S100B has also been proposed as a surrogate marker
for successful clot lysis in patients with proximal middle
cerebral artery occlusion who had received intravenous
thrombolysis. One study reported that a single S100B
measurement of $<0.4 \mu\text{g/l}$ obtained 48–96 h after stroke
onset indicates early ($<6 \text{ h}$) reperfusion [28]. Moreover,


\begin{figure}
\centering
\includegraphics[width=\textwidth]{fig1.pdf}
\caption{Temporal profile of serum S100B release after acute isch-
aemic stroke. The dashed line corresponds to the normal level in
healthy subjects (data compiled from 6 longitudinal studies).}
\end{figure}


---

Cerebrovasc Dis 2009;27:295–302

299
final infarct volumes, measured on day 7 after stroke onset, were significantly smaller in patients with early recanalisation and larger in patients without recanalisation (p < 0.001). Therefore, these results appear to emphasise the strong correlation between serum S100B levels and final infarct volume as opposed to characterising S100B as an independent marker of vessel recanalisation.

S100B may have a role as a predictor of functional outcome [19–21, 24–27]. The majority of these studies examined S100B concentrations against different functional outcome scales including: Barthel Index, modified Rankin Score and Glasgow Outcome Score. Wunderlich et al. [25] found that a 48-hour S100B concentration over 0.2 µg/l in patients with acute infarction was a strong predictor of a poor functional outcome (sensitivity 85%, specificity 92%). Tauch et al. [27] observed worse outcomes at the 3-month follow-up in patients with faster rates of change in S100B concentrations over the first 24 h after stroke onset. Fassbender et al. [20] reported that neurological outcome was associated with serum S100 levels, but the only outcome measure used in this study was the Scandinavian Stroke Scale, a tool used to score neurological deficit and not outcome. Foerch et al. [26] reported that a 48-hour serum S100B level of ≥0.37 µg/l predicted an independent outcome (sensitivity 87%, specificity 78%). These latter authors demonstrated that S100B predicts outcome after acute stroke, independently of several variables including age, lesion side, National Institutes of Health Stroke Scale score, vascular risk factors and stroke aetiology. However, none of these studies evaluated whether S100B predicts clinical outcome independently of the final infarct volume, a variable that has been shown to significantly correlate with serum S100B levels [18–24].

Discussion

S100B continues to be widely studied as a biomarker for acute ischaemic stroke. In this article, we have proposed a number of criteria for assessing the utility of a biomarker in the management of stroke and used these to evaluate S100B.

Our review suggests that S100B is not a valuable biomarker for diagnosing acute ischaemic stroke because of its low specificity and delayed kinetics. In addition, we were unable to identify any studies that have directly compared serum S100B levels as an independent biomarker, between patients with acute cerebral infarction and stroke mimics. When included as part of a panel in the assessment of suspected strokes, including stroke mimics, the panel had too low a sensitivity and specificity to be useful in clinical practice. The compiled data from 6 longitudinal studies convincingly show a delayed peak in post-stroke S100B levels. This is in accordance with the current understanding of ischaemic brain injury, where only a small number of cells are subject to immediate necrosis and the remainder, for example those in the penumbral area, undergo a complex process leading to delayed death if perfusion is not restored [36]. However, for S100B to be a useful diagnostic biomarker for the selection of patients for thrombolysis in the emergency room, serum levels should be significantly raised within an hour of stroke onset even in patients who have normal CT brain imaging initially. In light of the temporal profile of serum S100B release, it is unlikely to prove to be a valuable tool for differentiating between ischaemic strokes and stroke mimics in the emergency room.

There is convincing evidence from a number of studies that S100B levels, measured beyond 24 h after stroke onset, correlate well with the final infarct volume [18–24]. It is hypothesised that S100B is released passively from necrotic astroglial cells after cerebral infarction. The main evidence for this comes from the finding that the ischaemic brain tissue, which survives after early vessel recanalisation, subsequently leading to a smaller final infarct volume, does not release S100B into the serum [28].

Studies have demonstrated that S100B measurements may be useful in identifying patients at increased risk of early neurological complications, e.g. malignant cerebral oedema or haemorrhage after thrombolysis. For both these post-stroke complications, infarct volume measurements on diffusion-weighted imaging have previously been shown to be a sensitive method for predicting which patients are at increased risk of these adverse events [37, 38]. In particular, Oppenheim et al. [37] reported that on diffusion-weighted imaging an infarct volume of >145 cm³ predicts patients at high risk of malignant cerebral oedema (sensitivity 100%, specificity 94%). Therefore, in specialist hospitals where stroke clinicians have immediate access to multimodal MRI, S100B measurements are unlikely to be helpful in identifying these patients.

Studies have also shown that S100B is a surrogate marker of functional outcome [19–21, 24–27]. However, accurate prediction of functional outcome after ischaemic stroke is difficult because of the significant heterogeneity of stroke. Even so, numerous predictors of functional outcome have been proposed and for any given patient there are several possible variables, with complex
interactions, which can contribute towards the patient’s functional outcome [39]. Several groups have tried to construct complex statistical models to predict outcome in acute stroke patients [40]. Despite this, no adequate model exists. Therefore, it is likely that S100B or any other biomarker for acute stroke will serve at best as an additional variable, amongst several others, capable of predicting functional outcome. However, it may have a more promising role in the research setting, as a surrogate marker in interventional stroke trials as an easily accessible and inexpensive outcome measure.

In conclusion, the evidence suggests that S100B is not a valuable biomarker for diagnosing acute ischaemic stroke. The main hurdles governing its use in the emergency room are its delayed kinetics and secondly its low specificity for cerebral infarction. However, serum S100B measurements beyond 24 h after stroke onset significantly correlate with final infarct volume, and in non-specialist hospitals it may be a more promising role, as an additional tool to help clinicians identify patients at high risk of specific early neurological complications. S100B levels correlate with functional outcome and may prove to be a useful and easy-to-perform outcome measure in stroke trials. Conversely, in specialist hospitals where patients are managed exclusively by stroke specialists and have immediate access to multimodal MRI, it is difficult to see how measuring S100B levels will provide any additional information in the management of acute stroke patients.

Acknowledgement

M.M.B.’s Chair is supported by the Rita Lila Weston Trust for Medical Research.

References


